Obstructive sleep apnea is a sleep disorder that causes your breathing to stop and start during the night. This can lead to loud snoring, disrupted rest and daytime fatigue, among other symptoms.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

Low-level laser therapy is a non-invasive treatment for TMJ symptoms that uses light to stimulate cellular activity, and it's ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The FDA advised that the medication be used in conjunction with a reduced-calorie diet and increased physical activity, both of which aid weight loss and, in turn, improve sleep apnea symptoms.

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...